Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens.
about
Diversity, evolution and medical applications of insect antimicrobial peptidesRecent advances in developing insect natural products as potential modern day medicinesDifferential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serumOptimization of oncocin for antibacterial activity using a SPOT synthesis approach: extending the pathogen spectrum to Staphylococcus aureus.Proline-rich antimicrobial peptides targeting protein synthesis.Peptide design for antimicrobial and immunomodulatory applications.Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design.In vivo Efficacy and Pharmacokinetics of Optimized Apidaecin Analogs.Potentiating the Activity of Nisin against Escherichia coli.Insect-derived short proline-rich and murine cathelicidin-related antimicrobial peptides act synergistically on Gram-negative bacteria in vitro.Progress with peptide scanning to study structure-activity relationships: the implications for drug discovery.The Mechanism of Killing by the Proline-Rich Peptide Bac7(1-35) against Clinical Strains of Pseudomonas aeruginosa Differs from That against Other Gram-Negative BacteriaCross-Linked Polymer-Stabilized Nanocomposites for the Treatment of Bacterial Biofilms.Short Proline-Rich Antimicrobial Peptides Inhibit Either the Bacterial 70S Ribosome or the Assembly of its Large 50S Subunit.N-Terminal Ile-Orn- and Trp-Orn-Motif Repeats Enhance Membrane Interaction and Increase the Antimicrobial Activity of Apidaecins against Pseudomonas aeruginosa.Specific tandem mass spectrometric detection of AGE-modified arginine residues in peptides.Oncocin Onc72 is efficacious against antibiotic-susceptible Klebsiella pneumoniae ATCC 43816 in a murine thigh infection model.Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome.Designed Host Defense Peptides for the Treatment of Bacterial Keratitis.Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo.An antimicrobial peptide that inhibits translation by trapping release factors on the ribosome.Correlating uptake and activity of proline-rich antimicrobial peptides in Escherichia coli.Antibiotic gold: tethering of antimicrobial peptides to gold nanoparticles maintains conformational flexibility of peptides and improves trypsin susceptibility.Controlled systemic release of therapeutic peptides from PEGylated prodrugs by serum proteases.Improving the Activity of Trp-Rich Antimicrobial Peptides by Arg/Lys Substitutions and Changing the Length of Cationic Residues.Antimicrobial peptidesDynamically crosslinked polymer nanocomposites to treat multidrug-resistant bacterial biofilms
P2860
Q26751067-AE1FC7E4-C4AF-493B-8945-52C752075A63Q33634334-6CEFAA83-2C54-4CB7-A9C2-EF4CF745AE76Q33757865-C3F996C8-782F-4B61-AC19-269431BB87C9Q35762892-49C136B2-A04B-45A9-84CA-8D61612C2FFEQ36379116-05C34D43-8947-49B7-93E5-F9492751A65FQ37598400-F9D71670-2589-449D-A387-0A7DC960FE8BQ37639825-2E662A8D-8A4F-46E6-B4A8-B801CF41B5F5Q37710376-4A490896-CF17-42D6-9AA2-B0B7F1AFB7CEQ38287543-0B0990ED-17B7-4D70-AE5D-86DEDFD24717Q38855258-FB6D2996-F548-4045-9E3C-7D820B25541BQ38867099-3722F9A3-5403-4A62-BDAA-147D83D5C35CQ40352859-5A9D1F5A-568E-4551-B6F4-26438B3EB328Q40398992-30CABEA5-BA48-4D1A-AECD-A5154C4E1AAEQ40453152-BC225D3F-4260-4DA6-80C8-E64C8738A656Q40652356-2E8B44C2-E245-4B76-81F2-4B90B0D878FDQ41176710-7FF80E4D-B557-4996-8DBD-C5D0A0E8953CQ41236257-EAADED80-E775-42CA-8CA4-5585B9CBE6CAQ41739821-E73EB184-D570-4C51-80A2-E5B0CB09F35DQ46683772-ECC5B153-5501-4F97-9858-DD803AD0967CQ47723258-988E9034-8849-42F3-B4D9-385E34FA5A91Q48031186-B14A64F7-F1B5-4D0D-9052-126697E21CBEQ48111070-82B972F0-D929-4BE1-8C65-50F63A34C98EQ48147426-2E5206BC-4DFD-4278-977D-0B94B449837DQ50908330-0108A8D6-05E0-415C-8E9A-23325998F27FQ52578359-D70A26C5-C246-4269-B477-27432B705B2FQ55982720-FF853A34-2A3A-4029-9C58-AE64E89CCF01Q57806963-5C16E056-01B4-4994-9779-E1B6189B6F18
P2860
Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by gram-negative pathogens.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Novel apidaecin 1b analogs wit ...... ns by gram-negative pathogens.
@ast
Novel apidaecin 1b analogs wit ...... ns by gram-negative pathogens.
@en
type
label
Novel apidaecin 1b analogs wit ...... ns by gram-negative pathogens.
@ast
Novel apidaecin 1b analogs wit ...... ns by gram-negative pathogens.
@en
prefLabel
Novel apidaecin 1b analogs wit ...... ns by gram-negative pathogens.
@ast
Novel apidaecin 1b analogs wit ...... ns by gram-negative pathogens.
@en
P2093
P2860
P356
P1476
Novel apidaecin 1b analogs wit ...... ns by gram-negative pathogens.
@en
P2093
Daniel Knappe
Gottfried Alber
Guido Schiffer
Nicole Berthold
Patricia Czihal
Ralf Hoffmann
Stefanie Fritsche
P2860
P304
P356
10.1128/AAC.01923-12
P407
P577
2012-10-31T00:00:00Z